Malvern Panalytical expands pharmaceutical drug development solutions through the acquisition of Creoptix

Malvern Panalytical, a company providing advanced analysis and services solutions for the pharma drug product development, as well as services and solutions for other industries, has today announced its acquisition of Creoptix AG, a specialist bioanalysis sensor company. The acquisition forms a critical part of Malvern Panalytical’s strategy to expand its capabilities in support of drug

Malvern Panalytical expands pharmaceutical drug development solutions through the acquisition of Creoptix2022-02-02T10:07:42+01:00

Creoptix launches new way of measuring kinetics to accelerate drug discovery

Creoptix, a Switzerland-based company focused on next-generation bioanalytical instruments, has launched waveRAPID (Repeated Analyte Pulses of Increasing Duration), a novel, label-free kinetic measurement method that is said to be faster than traditional kinetics. The company developed the Creoptix WAVEsystem to enable molecular interactions to be studied in real time, aimimng to revolutionise drug discovery. By

Creoptix launches new way of measuring kinetics to accelerate drug discovery2021-12-14T14:18:06+01:00

Domainex invests in the Creoptix WAVEdelta to strengthen its fragment-based drug discovery platform

Wädenswil/Zurich, Switzerland and Saffron Walden, UK, 12th January 2021 /  Sciad Newswire / Domainex Ltd., a leading provider of integrated drug discovery services, is pleased to announce that it has invested in the WAVEdelta instrument from Creoptix AG. This instrument utilizes Grating-Coupled Interferometry (GCI) to measure target binding on sensor chips, generating binding affinity and on/off rate kinetics in a high throughput manner.

Domainex invests in the Creoptix WAVEdelta to strengthen its fragment-based drug discovery platform2021-09-30T13:26:32+01:00

Swiss start-ups drive research around Covid-19

Not every Swiss start-up involved in Covid-19 research is developing a therapy. Companies also support researchers with digital tools, bioanalytical instruments and the production of proteins. Swiss start-ups are very active in the quest for therapies against Covid-19. You can find several examples in our article from 5 May. According to the weekly updated view

Swiss start-ups drive research around Covid-192021-09-30T14:40:53+01:00

Creoptix appoints Line Stigen Raquet as CEO

Wädenswil/Zurich, Switzerland, 10 December 2019 – Creoptix AG, a Switzerland-based company focused on next-generation bioanalytical instruments, today announced the appointment of Line Stigen Raquet as Chief Executive Officer with effect from beginning of January 2020. After seven years in the position, Matyas Vegh has decided to pursue new opportunities outside the company. “I am grateful

Creoptix appoints Line Stigen Raquet as CEO2021-09-30T15:02:30+01:00

Microfluidics mastery earns Switzerland’s Creoptix $8m Series C

Spare a thought for agri-tech companies out there focused on microfluidics — the swiftly advancing science of handling and manipulating tiny flows of fluids measured in microliters or picoliters. It’s key for crop science, and it is already bringing an ever deeper understanding of how crops react to light. Such increasingly precise measurements could improve

Microfluidics mastery earns Switzerland’s Creoptix $8m Series C2021-10-08T08:47:31+01:00

Creoptix raises CHF8m Series C financing round

Creoptix AG, a Switzerland-based company focused on next-generation bioanalytical instruments, has raised CHF8 million in the first closing of a Series C financing round. The round was led by Swisscanto Invest by Zürcher Kantonalbank and joined by Waters Corporation (NYSE: WAT) as well as existing private investors. Robert Schier of Swisscanto Invest has joined

Creoptix raises CHF8m Series C financing round2021-09-30T15:21:49+01:00
Go to Top